Screener
10x Genomics, Inc. TXG Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating activities: | ||
| Net income (loss) | $(31,401) | $180 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Stock-based compensation expense | 48,258 | 58,635 |
| Depreciation and amortization | 19,621 | 15,837 |
| Non-cash lease expense | 3,969 | 3,628 |
| Fair value adjustments on contingent consideration | 3,466 | — |
| Asset and lease impairment charges | — | 114 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is 10x Genomics, Inc.'s stock-based comp?
- 10x Genomics, Inc. (TXG) reported stock-based comp of $25.62M in Q2 2026.
- How has 10x Genomics, Inc.'s stock-based comp changed year-over-year?
- 10x Genomics, Inc.'s stock-based comp decreased by 7.1% year-over-year, from $27.56M to $25.62M.
- What is the long-term trend for 10x Genomics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), 10x Genomics, Inc.'s stock-based comp has grown at a 3.3% compound annual growth rate (CAGR), from $95.96M to $109.12M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about 10x Genomics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude